|
KMID : 1146920230530030427
|
|
Journal of Pharmaceutical Investigation
2023 Volume.53 No. 3 p.427 ~ p.441
|
|
|
Establishment of a fexofenadine population pharmacokinetic (PK)?pharmacodynamic (PD) model and exploration of dosing regimens through simulation
|
|
Jang Ji-Hun
Jeong Seung-Hyun
Lee Yong-Bok
|
|
|
Abstract
|
|
|
Purpose : Fexofenadine is an antihistamine drug used to treat various allergic diseases. Despite long-term clinical application, research and knowledge on setting dosage regimen based on quantitative pharmacometrics prediction are still very lacking. This study aimed to explore the dosing regimen of fexofenadine through establishment of a fexofenadine population pharmacokinetic (PK)?pharmacodynamic (PD) model and model simulation. We also assessed whether ATP-binding cassette-subfamily-B-member-1 (ABCB1) gene polymorphism is associated with interindividual variability in fexofenadine PKs.
Methods : For this study, the results of fexofenadine bioequivalence study on healthy Korean males and previously reported PK and PD results were used. Based on these data, a fexofenadine population PK?PD model was established.
Results : ABCB1 gene polymorphisms were not significantly correlated with interindividual PK diversity of fexofenadine. This result suggests that considering ABCB1 gene polymorphisms would not be significantly beneficial in individualized therapy using fexofenadine. The established model well explained the PK?PD outcomes of fexofenadine at various doses in healthy adults. Model simulation revealed that the maximum PD (Rmax) values at approximately 200?4000 mg doses of fexofenadine did not differ largely (approximately 10%); however, fivefold to eightfold differences were noted between Rmax and the subsequent minimum PD (Rmin) values. Moreover, the degree of decrease in the average fexofenadine PDs in the steady?state according to increase in the dosing interval (6?24 h) for same dose was within 5%, whereas the difference between Rmax and Rmin for prolonging PD response was as large as 7%. This result suggests that effective therapy for allergy could involve increasing oral dosage of fexofenadine and reducing dosing interval to prolong the PD effect.
Conclusion : Our findings can provide a clearer direction for personalized therapy using fexofenadine in clinical setting through qualitative?quantitative predictions.
|
|
|
KEYWORD
|
|
|
Fexofenadine, Pharmacokinetics, Pharmacodynamics, ABCB1, Population modeling, Model simulation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|